161 related articles for article (PubMed ID: 34311790)
41. Large-scale evaluation of ion mobility spectrometry for the rapid detection of synthetic cannabinoid receptor agonists in infused papers in prisons.
Norman C; McKirdy B; Walker G; Dugard P; NicDaéid N; McKenzie C
Drug Test Anal; 2021 Mar; 13(3):644-663. PubMed ID: 33058556
[TBL] [Abstract][Full Text] [Related]
42. Typology of new psychoactive substance use among the general Australian population.
Sutherland R; Peacock A; Roxburgh A; Barratt MJ; Burns L; Bruno R
Drug Alcohol Depend; 2018 Jul; 188():126-134. PubMed ID: 29775956
[TBL] [Abstract][Full Text] [Related]
43. New synthetic cannabinoids and the potential for cardiac arrhythmia risk.
Hancox JC; Copeland CS; Harmer SC; Henderson G
J Mol Cell Cardiol Plus; 2023 Dec; 6():100049. PubMed ID: 38143960
[TBL] [Abstract][Full Text] [Related]
44. Human Toxicity Caused by Indole and Indazole Carboxylate Synthetic Cannabinoid Receptor Agonists: From Horizon Scanning to Notification.
Hill SL; Dunn M; Cano C; Harnor SJ; Hardcastle IR; Grundlingh J; Dargan PI; Wood DM; Tucker S; Bartram T; Thomas SHL
Clin Chem; 2018 Feb; 64(2):346-354. PubMed ID: 29038156
[TBL] [Abstract][Full Text] [Related]
45. Synthetic cannabinoid receptor agonists-induced recurrent seizure in elderly patient.
Andreias L; Roffe E; Eng A; Yiu K; Pashmforoosh G; Khan Z; Rahman R; Kalantari H; Hassen GW
Am J Emerg Med; 2020 Apr; 38(4):850.e5-850.e6. PubMed ID: 31839517
[TBL] [Abstract][Full Text] [Related]
46. "Walking the nitrogen around the ring": Chemical synthesis and spectroscopic characterization of novel 4-, 5-, 6-, and 7-azaindazole analogs of the synthetic cannabinoid receptor agonist MDMB-PINACA.
Alam RM; Keating JJ
Drug Test Anal; 2022 Feb; 14(2):277-297. PubMed ID: 34654062
[TBL] [Abstract][Full Text] [Related]
47. CUMYL-4CN-BINACA Is an Efficacious and Potent Pro-Convulsant Synthetic Cannabinoid Receptor Agonist.
Kevin RC; Anderson L; McGregor IS; Boyd R; Manning JJ; Glass M; Connor M; Banister SD
Front Pharmacol; 2019; 10():595. PubMed ID: 31191320
[TBL] [Abstract][Full Text] [Related]
48. Synthetic cannabinoid withdrawal: a new demand on detoxification services.
Macfarlane V; Christie G
Drug Alcohol Rev; 2015 Mar; 34(2):147-53. PubMed ID: 25588420
[TBL] [Abstract][Full Text] [Related]
49. Synthetic cannabinoid use among college students.
Mathews EM; Jeffries E; Hsieh C; Jones G; Buckner JD
Addict Behav; 2019 Jun; 93():219-224. PubMed ID: 30772774
[TBL] [Abstract][Full Text] [Related]
50. First European case of convulsions related to analytically confirmed use of the synthetic cannabinoid receptor agonist AM-2201.
McQuade D; Hudson S; Dargan PI; Wood DM
Eur J Clin Pharmacol; 2013 Mar; 69(3):373-6. PubMed ID: 22936123
[TBL] [Abstract][Full Text] [Related]
51. Do Toxic Synthetic Cannabinoid Receptor Agonists Have Signature in Vitro Activity Profiles? A Case Study of AMB-FUBINACA.
Finlay DB; Manning JJ; Ibsen MS; Macdonald CE; Patel M; Javitch JA; Banister SD; Glass M
ACS Chem Neurosci; 2019 Oct; 10(10):4350-4360. PubMed ID: 31513380
[TBL] [Abstract][Full Text] [Related]
52. Synthetic Cannabinoid Receptor Agonists in Postmortem Casework in Scotland.
Seywright A; Irvine AFD; McKeown DA; Wylie FM; Torrance HJ
J Anal Toxicol; 2023 Jan; 46(9):1066-1072. PubMed ID: 34994788
[TBL] [Abstract][Full Text] [Related]
53. Synthetic Cannabinoid Receptor Agonists Detection Using Fluorescence Spectral Fingerprinting.
May B; Naqi HA; Tipping M; Scott J; Husbands SM; Blagbrough IS; Pudney CR
Anal Chem; 2019 Oct; 91(20):12971-12979. PubMed ID: 31580647
[TBL] [Abstract][Full Text] [Related]
54. Recent Use of Synthetic Cannabinoids, Synthetic Opioids, and Other Psychoactive Drug Groups among High-risk Drug Users.
Shapira B; Berkovitz R; Rosca P; Neumark Y
J Psychoactive Drugs; 2020; 52(4):334-343. PubMed ID: 32345134
[TBL] [Abstract][Full Text] [Related]
55. Quantitation of Synthetic Cannabinoid Receptor Agonists in Postmortem Blood Using a Single Point Calibration.
Sharp P; Hudson S; Morley SR
Acad Forensic Pathol; 2021 Jun; 11(2):75-82. PubMed ID: 34567326
[TBL] [Abstract][Full Text] [Related]
56. Increases in synthetic cannabinoids-related harms: Results from a longitudinal web-based content analysis.
Lamy FR; Daniulaityte R; Nahhas RW; Barratt MJ; Smith AG; Sheth A; Martins SS; Boyer EW; Carlson RG
Int J Drug Policy; 2017 Jun; 44():121-129. PubMed ID: 28578250
[TBL] [Abstract][Full Text] [Related]
57. In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018.
Gamage TF; Barrus DG; Kevin RC; Finlay DB; Lefever TW; Patel PR; Grabenauer MA; Glass M; McGregor IS; Wiley JL; Thomas BF
Pharmacol Biochem Behav; 2020 Jun; 193():172918. PubMed ID: 32247816
[TBL] [Abstract][Full Text] [Related]
58. Clinical toxicity following analytically confirmed use of the synthetic cannabinoid receptor agonist MDMB-CHMICA. A report from the Identification Of Novel psychoActive substances (IONA) study.
Hill SL; Najafi J; Dunn M; Acheampong P; Kamour A; Grundlingh J; Blain PG; Thomas SH
Clin Toxicol (Phila); 2016 Sep; 54(8):638-43. PubMed ID: 27251903
[TBL] [Abstract][Full Text] [Related]
59. [Cannabis and schizophrenia: demographic and clinical correlates].
Dervaux A; Laqueille X; Bourdel MC; Leborgne MH; Olié JP; Lôo H; Krebs MO
Encephale; 2003; 29(1):11-7. PubMed ID: 12640322
[TBL] [Abstract][Full Text] [Related]
60. Differential physiological and behavioral cues observed in individuals smoking botanical marijuana versus synthetic cannabinoid drugs.
Chase PB; Hawkins J; Mosier J; Jimenez E; Boesen K; Logan BK; Walter FG
Clin Toxicol (Phila); 2016; 54(1):14-9. PubMed ID: 26653952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
